Skip to main content
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc. — Investor Relations & Filings

Ticker · CLRB ISIN · US15117F8077 LEI · 5493000NFZCRG7BYQV93 US Manufacturing
Open in API
Filings indexed 1,033 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country US United States of America
Listing US CLRB

About Cellectar Biosciences, Inc.

https://www.cellectar.com/

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Recent filings

Filing Released Lang Actions
424B3
Regulatory Filings Classification · 86% confidence The document is a SEC Form 424B3 prospectus filed pursuant to Rule 424(b)(3) relating to the resale of shares by selling stockholders, detailing a private placement, warrants, and registration of shares. It is not an Annual Report, Earnings Release, Prospectus Presentation (Investor Presentation), nor a board or management change notice, nor a voting proxy, call transcript, or ESG report. No category explicitly covers a securities prospectus, so it defaults to Regulatory Filings (RNS) as a miscellaneous SEC compliance filing.
2026-06-02 English
FORM S-1/A
Regulatory Filings Classification · 90% confidence The document is an SEC registration statement and prospectus (Form S-1/A) for the resale of shares by selling stockholders. It is not an annual or quarterly financial report, nor a management change, earnings release, or investor presentation. It constitutes a regulatory filing (registration statement) under the Securities Act. Therefore it falls under the ‘Regulatory Filings’ category (RNS).
2026-05-29 English
DEFA14A
Proxy Solicitation & Information Statement
2026-05-28 English
DEF 14A
Proxy Solicitation & Information Statement
2026-05-28 English
FORM S-1
Regulatory Filings
2026-05-19 English
FORM 8-K
Board/Management Information Classification · 92% confidence The document is a Form 8-K current report under Item 5.02, detailing the departure of a Class III director, a consulting arrangement, and the appointment of a new board member and audit committee member. It clearly announces changes in the company’s board of directors and related management arrangements. This fits the Board/Management Information category.
2026-05-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.